BiologicalDrug
OBI-821 clinical trials
- studies test it
- 8
- open now
- 4
- in phase 3
- 0
- first study started
- 2011
Keep track of what changes. Save the OBI-821 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 5
OBI Pharma, Inc (3) · Chang Gung Memorial Hospital (2) · Memorial Sloan Kettering Cancer Center (1) · National Taiwan University Hospital (1) · Mackay Memorial Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses OBI-821 is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Study of a Vaccine in Combination With Beta-glucan in People With NeuroblastomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06057948Written as OPT-821 (QS-21)
- To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 2OBI Pharma, IncNCT05442060Written as 30 μg OBI-833/100 μg OBI-821
- Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/CisplatinNot yet recruitingPhase 1Chang Gung Memorial HospitalNCT06490198Written as OBI-833/OBI-821
- To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for RecurrenceRecruitingPhase 2National Taiwan University HospitalNCT05376423Written as OBI-833/OBI-821
- Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer SubjectsCompletedPhase 1OBI Pharma, IncNCT02310464Written as OBI-833/OBI-821
- Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT GenotypeTerminatedPhase 2Chang Gung Memorial HospitalNCT03608878Written as adagloxad simolenin/OBI-821
- Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer SubjectsCompletedPhase 2OBI Pharma, IncNCT01516307Written as OPT-822/OPT-821(30 μg/100 μg)
- Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian CancerStatus unknownPhase 2Mackay Memorial HospitalNCT02132988Written as OPT-822/OPT-821
Given in every arm · 2 — OBI-821 is usual care beside what is tested
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04936529Written as OPT-821
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete RemissionCompletedPhase 2Gynecologic Oncology GroupNCT00857545Written as Saponin-based Immunoadjuvant OBI-821
As the comparator · 1 — what is tested is compared with OBI-821
Codes
What other systems call OBI-821 · ClinicalTrials.gg INT017352
- UNII (FDA) N3HYX1U87COBI-821One source FDA
- NCI Thesaurus C91726Saponin-based Immunoadjuvant OBI-821One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N3HYX1U87C | OBI-821 | One source FDA |
| NCI Thesaurus | C91726 | Saponin-based Immunoadjuvant OBI-821 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.